What Is CJC-1295? Uses, Benefits, Safety, FDA Status, and Evidence
Medical review note: This article is for educational purposes only and does not provide medical advice. CJC-1295 is not FDA-approved for human therapeutic use. Products sold online as CJC-1295, CJC-1295 DAC, or “research use only” CJC-1295 may carry serious safety, quality, and legal risks.
Quick answer
CJC-1295 is a synthetic analog of growth hormone-releasing hormone, also called GHRH or growth hormone-releasing factor. It was designed to stimulate the pituitary gland to release growth hormone, which can increase insulin-like growth factor 1, also called IGF-1. The best-known form is CJC-1295 with DAC, where DAC stands for drug affinity complex, a modification intended to extend the peptide’s half-life. Small human studies show that CJC-1295 can raise growth hormone and IGF-1 levels, but it is not FDA-approved, FDA has raised safety concerns about compounded CJC-1295, and CJC-1295 is prohibited in competitive sport.
Key facts about CJC-1295
| Question | Answer |
|---|---|
| What is CJC-1295? | A synthetic growth hormone-releasing hormone analog. |
| Other names | CJC-1295 DAC, DAC:GRF, long-acting GHRH analog. |
| Drug class | Growth hormone-releasing hormone analog / growth hormone secretagogue. |
| Main mechanism | Stimulates pituitary growth hormone release, which can increase IGF-1. |
| FDA-approved? | No. CJC-1295 is not an FDA-approved drug. |
| Main studied uses | Growth hormone and IGF-1 stimulation; investigated historically for growth-hormone-related conditions and lipodystrophy. |
| Human evidence level | Limited. Small short-duration human studies show GH and IGF-1 increases. |
| Common online claims | “Increases HGH,” “fat loss,” “muscle growth,” “recovery,” “anti-aging,” “better sleep.” |
| Sports status | Prohibited by WADA; listed under peptide hormones/growth hormone-releasing factors. |
| Main safety concern | FDA-identified safety concerns, limited clinical data, possible immunogenicity, peptide impurities, API characterization issues, and unapproved online products. |
What is CJC-1295?
CJC-1295 is a synthetic analog of growth hormone-releasing hormone. Growth hormone-releasing hormone is a naturally occurring hormone that signals the pituitary gland to release growth hormone.
CJC-1295 is often discussed as CJC-1295 with DAC, also called DAC:GRF. DAC stands for drug affinity complex. The DAC modification was designed to bind albumin and make the peptide last longer in the body.
The 2006 Journal of Clinical Endocrinology & Metabolism study on CJC-1295 reported that subcutaneous administration of CJC-1295 produced sustained, dose-dependent increases in growth hormone and IGF-1 levels in healthy adults.
The key distinction:
CJC-1295 can affect growth hormone biology, but that does not make it an FDA-approved anti-aging, fat-loss, recovery, or muscle-building treatment.
CJC-1295 vs CJC-1295 DAC
Online content often uses “CJC-1295” loosely. That creates confusion.
| Term | Meaning |
|---|---|
| CJC-1295 | Broad term often used online for related GHRH analog products. |
| CJC-1295 DAC | Long-acting form with a drug affinity complex designed to extend half-life. |
| DAC:GRF | Another name for CJC-1295 with DAC. |
| CJC-1295 without DAC | Often used online, but terminology can be inconsistent. |
| Mod GRF 1-29 | Related GHRH analog, but not the same as CJC-1295 DAC. |
The FDA PCAC briefing document on CJC-1295-related bulk drug substances evaluated multiple CJC-1295-related substances, including CJC-1295 free base, CJC-1295 acetate, CJC-1295 DAC free base, CJC-1295 DAC acetate, and CJC-1295 DAC TFA. FDA noted concerns about inconsistent naming and characterization of these substances.
The practical interpretation:
When a seller says “CJC-1295,” you need to know exactly which form they mean. The name alone is not enough.
How does CJC-1295 work?
CJC-1295 is intended to activate the GHRH pathway. It signals the pituitary gland to release growth hormone. Increased growth hormone can then increase IGF-1, a downstream growth factor involved in growth, metabolism, and tissue-related signaling.
In a PubMed-indexed human study, CJC-1295 increased growth hormone and IGF-1 levels in healthy adults. Another PubMed-indexed analysis examined biomarkers of GH and IGF-1 axis activation after CJC-1295 exposure.
But mechanism is not proof.
A proposed hormonal mechanism does not prove that CJC-1295 reverses aging, burns fat, builds muscle, improves sleep, accelerates injury recovery, or safely improves performance in healthy adults. The quality of evidence depends on controlled human studies in the specific population and outcome being claimed.
What is CJC-1295 used for?
CJC-1295 is commonly discussed for growth hormone optimization, anti-aging, fat loss, muscle growth, sleep, recovery, and body composition. The evidence quality varies sharply by claim.
| Use | Evidence level | What is known | What is not known |
|---|---|---|---|
| Growth hormone and IGF-1 stimulation | Limited human evidence | Small human studies show CJC-1295 can increase GH and IGF-1. | Long-term safety and clinical utility are not established. |
| Growth hormone deficiency | Not established | FDA evaluated CJC-1295-related substances for GHD compounding context. | FDA identified lack of clinical effectiveness data for GHD and approved alternatives exist. |
| Lipodystrophy | Investigational history | CJC-1295 was investigated historically in lipodystrophy. | A phase 2 study was halted after a participant death, with relationship to the drug under investigation at the time. |
| Anti-aging | Unsupported | Common clinic and online claim. | No strong clinical evidence proves anti-aging or longevity benefits. |
| Fat loss/body composition | Weak / extrapolated | GH/IGF-1 biology may affect body composition. | Not proven as a safe, effective fat-loss treatment in healthy adults. |
| Muscle growth/recovery | Weak / extrapolated | Often marketed to athletes and bodybuilders. | Not proven for performance or recovery, and prohibited in sport. |
| Online CJC-1295 products | High uncertainty | Often sold as research-use peptide products. | Quality, sterility, dosing, identity, and safety may be unknown. |
What does the research show?
Human evidence
The best-known human trial is the 2006 study in healthy adults.
The JCEM study on CJC-1295 found that subcutaneous CJC-1295 caused sustained, dose-dependent increases in growth hormone and IGF-1. The PubMed summary describes CJC-1295 as producing sustained GH and IGF-1 increases in healthy adults.
This supports the basic biological claim:
CJC-1295 can raise GH and IGF-1 in humans.
But that study does not prove that CJC-1295 safely treats anti-aging, muscle growth, fat loss, sleep, injury recovery, or general wellness in healthy adults.
Human evidence limitations
The FDA’s review of CJC-1295-related bulk drug substances found that available clinical safety information was limited. The FDA PCAC briefing document states that the available studies were conducted in healthy adults, had small sample sizes, and were short in duration, despite the substance being proposed for a chronic condition.
The practical interpretation:
CJC-1295 has evidence for biomarker changes, but it lacks strong clinical-outcome evidence and long-term safety data.
Lipodystrophy study history
CJC-1295 also has a concerning historical note.
A 2006 aidsmap report reported that a phase 2 lipodystrophy study of CJC-1295, also known as DAC:GRF, was halted after the death of a study participant. The cause of death and its relationship to the study drug were being investigated at the time.
This does not prove that CJC-1295 caused the death.
But it does mean the development history is not something serious readers should ignore.
Evidence summary
| Claim | Evidence verdict | Explanation |
|---|---|---|
| “CJC-1295 increases growth hormone and IGF-1.” | Supported by limited human evidence | Small human studies show sustained GH and IGF-1 increases. |
| “CJC-1295 is FDA-approved.” | False | CJC-1295 is not an FDA-approved drug. |
| “CJC-1295 treats growth hormone deficiency.” | Not established | FDA found insufficient clinical effectiveness data for evaluated CJC-1295 substances in GHD. |
| “CJC-1295 builds muscle.” | Weak / extrapolated | Often inferred from GH/IGF-1 biology, not proven by strong clinical outcomes. |
| “CJC-1295 burns fat.” | Weak / extrapolated | Body-composition claims are not supported by strong approval-level evidence. |
| “CJC-1295 reverses aging.” | Unsupported | Anti-aging and longevity claims are not established. |
| “CJC-1295 is safe because it is a peptide.” | False | FDA has identified serious adverse events and limited clinical data. |
| “CJC-1295 is allowed for athletes.” | False | WADA lists CJC-1295 as prohibited. |
| “Research-use CJC-1295 is the same as clinical-trial CJC-1295.” | Misleading | Online products may differ in identity, purity, sterility, salt form, concentration, and quality controls. |
Is CJC-1295 FDA-approved?
No. CJC-1295 is not FDA-approved.
The FDA page on bulk drug substances that may present significant safety risks states that compounded drugs containing CJC-1295 may pose risks related to immunogenicity, peptide impurities, and API characterization. FDA also says it has identified serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilatory reaction.
The FDA PCAC briefing document proposed not adding multiple CJC-1295-related bulk drug substances to the 503A Bulks List because of concerns including inconsistent characterization, limited historical compounding information, possible safety concerns from nonclinical toxicology, limited clinical safety data, and lack of clinical effectiveness data for growth hormone deficiency.
The key distinction:
CJC-1295 is a biologically active investigational peptide, not an FDA-approved prescription medication.
Is CJC-1295 legal?
CJC-1295’s legal status depends on product type, use, and jurisdiction, but the practical answer is simple:
CJC-1295 is not an FDA-approved drug, and online availability does not mean it is legally marketed for human therapeutic use.
Some sellers market CJC-1295 as a research peptide. That does not make it safe, approved, or appropriate for consumer use.
The blunt version:
Buying “research use only” CJC-1295 from an online seller is not the same as receiving an FDA-approved prescription drug from a legitimate pharmacy.
Is CJC-1295 banned in sports?
Yes. CJC-1295 is prohibited in competitive sport.
The WADA 2026 Prohibited List lists CJC-1295 by name. WADA also lists growth hormone-releasing factors and related analogues as prohibited substances.
For athletes, the answer is simple:
Do not use CJC-1295 if you are subject to anti-doping rules.
Safety and side effects
CJC-1295 has real biological activity. It should not be treated like a harmless supplement.
Possible or reported concerns include:
- Increased heart rate
- Systemic vasodilatory reaction
- Injection-site reactions
- Headache
- Flushing
- Nausea
- Dizziness
- Changes in GH and IGF-1 signaling
- Possible glucose or metabolic effects
- Immunogenicity risk
- Peptide impurity risk
- Product-quality and sterility risk from online sources
FDA specifically identifies serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilatory reaction. FDA also says available clinical data are limited.
The FDA PCAC briefing document also described nonclinical safety concerns for CJC-1295 DAC forms, including local injection-site findings in rats and dogs, genotoxic safety signals in certain studies, and inability to rule out pituitary hyperplasia or tumor risk from long-term overstimulation of somatotrophs.
A serious evaluation of CJC-1295 should separate controlled clinical research from online peptide products.
CJC-1295 vs similar peptides
| Compound | Category | Main difference |
|---|---|---|
| CJC-1295 | GHRH analog | Long-acting growth hormone-releasing hormone analog; not FDA-approved. |
| CJC-1295 DAC | Long-acting GHRH analog | DAC modification is intended to extend half-life through albumin binding. |
| Sermorelin | GHRH analog | Historically FDA-approved as Geref, now discontinued; shorter-acting than CJC-1295 DAC. |
| Ipamorelin | Growth hormone secretagogue | Stimulates GH through ghrelin receptor pathways, not GHRH receptor pathways. |
| Tesamorelin | GHRH analog | FDA-approved as Egrifta products for excess abdominal fat in adults with HIV and lipodystrophy. |
| Human growth hormone | Recombinant hormone | Supplies growth hormone directly instead of stimulating endogenous release. |
| BPC-157 | Experimental repair peptide | Not a growth-hormone-related peptide. |
The key distinction:
CJC-1295 belongs in the growth-hormone secretagogue category. It is not a tissue-repair peptide, GLP-1 drug, or approved anti-aging medication.
Why is CJC-1295 sold as “research use only”?
Some online sellers use “research use only” language to sell CJC-1295 outside normal prescription-drug channels.
That label is not a trust signal.
A serious reader should understand this distinction:
| Product type | What it means |
|---|---|
| Clinical-study CJC-1295 | Controlled research product used under study conditions. |
| FDA-approved CJC-1295 | Does not currently exist. |
| Compounded CJC-1295 | FDA has raised safety and characterization concerns around compounded CJC-1295. |
| Research-use CJC-1295 | Not an FDA-approved consumer therapeutic product. |
| Online peptide CJC-1295 | Higher risk for identity, sterility, dosing, and quality problems. |
How to evaluate CJC-1295 claims online
| Claim | What to verify |
|---|---|
| “FDA-approved CJC-1295” | False. CJC-1295 is not FDA-approved. |
| “Boosts HGH naturally” | It can stimulate GH pathways, but that does not prove broad clinical benefit. |
| “Builds muscle and burns fat” | Look for controlled human outcome trials, not just GH/IGF-1 biomarker changes. |
| “Anti-aging peptide” | Unsupported by strong clinical evidence. |
| “No side effects” | False. FDA has identified serious adverse events and limited clinical data. |
| “CJC-1295 without DAC is safer” | Requires evidence. Form and characterization matter. |
| “Research use only” | This does not mean safe, legal, approved, or appropriate for human use. |
| “Safe for athletes” | False. WADA lists CJC-1295 as prohibited. |
| “Same as sermorelin” | False. Both are GHRH-related, but they are not the same substance. |
| “Third-party tested” | Ask for recent batch-specific HPLC, LC-MS, identity, purity, and sterility data. |
Bottom line
CJC-1295 is a synthetic growth hormone-releasing hormone analog designed to stimulate growth hormone and IGF-1. Small human studies show that it can raise GH and IGF-1, especially in DAC-modified form, but it is not FDA-approved, has limited long-term human safety data, and FDA has raised safety and characterization concerns around compounded CJC-1295.
The most defensible conclusion is:
CJC-1295 is biologically active and clinically interesting, but most online claims about anti-aging, fat loss, muscle growth, sleep, and recovery go beyond the strongest evidence. Athletes should avoid it because WADA lists CJC-1295 as prohibited.
FAQ
What is CJC-1295?
CJC-1295 is a synthetic growth hormone-releasing hormone analog designed to stimulate pituitary growth hormone release and increase IGF-1.
What is CJC-1295 DAC?
CJC-1295 DAC is a longer-acting form of CJC-1295. DAC stands for drug affinity complex, a modification intended to extend the peptide’s half-life by binding albumin.
What does CJC-1295 do?
CJC-1295 stimulates the growth hormone-releasing hormone pathway, which can increase growth hormone and IGF-1 levels. This does not prove broad anti-aging, fat-loss, muscle-building, or recovery benefits.
Is CJC-1295 FDA-approved?
No. CJC-1295 is not FDA-approved. FDA has raised concerns about compounded CJC-1295, including limited clinical data, immunogenicity risk, peptide impurities, API characterization issues, and identified serious adverse events.
Is CJC-1295 the same as sermorelin?
No. Both are GHRH-related peptides, but they are different substances. CJC-1295 DAC is designed to be longer-acting, while sermorelin is GHRH 1-29 and was historically marketed as Geref.
Is CJC-1295 the same as ipamorelin?
No. CJC-1295 is a GHRH analog. Ipamorelin is a growth hormone secretagogue that works through ghrelin receptor pathways.
Does CJC-1295 build muscle?
Muscle-building claims are not well established. CJC-1295 can increase GH and IGF-1 biomarkers, but that does not prove safe or reliable muscle growth in healthy adults.
Does CJC-1295 burn fat?
Fat-loss claims are mostly extrapolated from growth hormone biology. CJC-1295 is not FDA-approved as a fat-loss medication.
Is CJC-1295 safe?
CJC-1295 does not have enough long-term human safety data to call it safe. FDA has identified serious adverse events and says available clinical data are limited.
Is CJC-1295 banned in sports?
Yes. WADA lists CJC-1295 as prohibited. Athletes subject to anti-doping rules should avoid it.
Why do sellers call CJC-1295 “research use only”?
Sellers often use “research use only” language because CJC-1295 is not FDA-approved for consumer therapeutic use. The phrase does not make the product safe, legal, approved, or clinically proven.
What is the biggest risk with CJC-1295?
The biggest risks are using an unapproved hormone-active peptide without medical supervision, relying on unsupported anti-aging or performance claims, and buying online products with uncertain identity, purity, sterility, concentration, and safety.
Sources
- FDA: Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks
- FDA: CJC-1295 PCAC Briefing Document
- FDA: PCAC Points to Consider for CJC-1295-Related Bulk Drug Substances
- JCEM: Prolonged Stimulation of GH and IGF-1 Secretion by CJC-1295
- PubMed: Prolonged Stimulation of GH and IGF-1 Secretion by CJC-1295
- PubMed: Pulsatile Secretion of GH Persists During CJC-1295 Treatment
- PMC: Activation of the GH/IGF-1 Axis by CJC-1295
- aidsmap: Lipodystrophy Study Halted After Patient Death
- WADA: 2026 Prohibited List
- WADA: Prohibited List
Frequently asked questions
What is CJC-1295?
CJC-1295 is a synthetic growth hormone-releasing hormone analog designed to stimulate pituitary growth hormone release and increase IGF-1.
What is CJC-1295 DAC?
CJC-1295 DAC is a longer-acting form of CJC-1295. DAC stands for drug affinity complex, a modification intended to extend the peptide's half-life by binding albumin.
Is CJC-1295 FDA-approved?
No. CJC-1295 is not FDA-approved. FDA has raised concerns about compounded CJC-1295, including limited clinical data, immunogenicity risk, peptide impurities, API characterization issues, and identified serious adverse events.
Is CJC-1295 the same as sermorelin?
No. Both are GHRH-related peptides, but they are different substances. CJC-1295 DAC is designed to be longer-acting, while sermorelin is GHRH 1-29 and was historically marketed as Geref.
Does CJC-1295 build muscle?
Muscle-building claims are not well established. CJC-1295 can increase GH and IGF-1 biomarkers, but that does not prove safe or reliable muscle growth in healthy adults.
Is CJC-1295 safe?
CJC-1295 does not have enough long-term human safety data to call it safe. FDA has identified serious adverse events and says available clinical data are limited.
Is CJC-1295 banned in sports?
Yes. WADA lists CJC-1295 as prohibited. Athletes subject to anti-doping rules should avoid it.
Sources
- [1]
- [2]FDA: CJC-1295 PCAC Briefing Document
Regulatory
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]aidsmap: Lipodystrophy Study Halted After Patient Death
Clinical History
- [9]WADA: 2026 Prohibited List
Anti Doping
- [10]WADA: Prohibited List
Anti Doping
Last updated May 9, 2026